Sleep problems in Parkinson’s disease: a community-based study in Norway

1471-2377-12-71 1471-2377 Research article Sleep problems in Parkinson’s disease: a community-based study in Norway SvenssonElisabethelisabeth.svensson@dce.au.dk BeiskeGAntoineagbeiske@gmail.com LogeHåvardJonj.h.loge@medisin.uio.no BeiskeKKorneliaKornelia.Katalin.Beiske@ahus.no SivertsenBørgeborge.sivertsen@fhi.no

Department of Adult Mental Health, Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway

Department of Neurology, Akershus University Hospital, Akershus, Norway

National Resource Centre for Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway

Department of Behavioural Sciences, University of Oslo, Oslo, Norway

Department of Clinical Psychology, University of Bergen, Bergen, Norway

Division of Psychiatry, Helse Fonna HF, Haugesund, Norway

BMC Neurology 1471-2377 2012 12 1 71 http://www.biomedcentral.com/1471-2377/12/7110.1186/1471-2377-12-7122883600 151220116820121082012 2012Svensson et al.; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sleep Parkinson Prevalence Norway Associated factors

Abstract

Background

The purpose of this study was to examine the prevalence of sleep problems in a community-based sample of patients with Parkinson’s disease (PD) in Norway, and their associated factors.

Methods

176 consecutive PD outpatients (41% females) were included in a study of non-motor symptoms, including sleep problems. All participants responded to the Parkinson’s Disease Sleep Scale (PDSS), where an overall score below 82 or a score below 5 on a sub-item indicate possible sleep problem. Factors associated with sleep were also investigated, with special emphasis on severity of PD, fatigue, mental health and restless legs syndrome (RLS).

Results

The mean age was 68.5 years (range 35–90); the mean Hoehn and Yahr stage was 2.11 (SD 0.86), and the mean UPDRS part III was 22.3 (SD 11.7). Sleep problems were common among PD patients. While only 17% of the sample had an overall score below 82 on the PDSS, 70% of the patients had a score below 5 on one item. There was no significant association between PD severity and any of the sleep items in the PDSS; whereas fatigue, mental health problems, and RLS were associated with PDSS score.

Conclusions

The current findings call for increased awareness of sleep problems in PD patients, especially focusing on the association with mental health problems, fatigue and RLS.

Background

Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, and primarily affects the elderly: while approximately 1% of people aged 65 to 69 suffer from PD, the prevalence increases to nearly 5% among people aged 80 to 84 1. PD is characterized not only by movement abnormalities, but also by non-motor symptoms such as fatigue, pain, and sleep problems 2 3 4. Sleep problems are common; community studies have reported that about 60% of PD patients had a sleep disorder compared to 33% of the controls 5. Common sleep problems include insomnia symptoms (difficulty initiating and maintaining sleep), excessive daytime somnolence, and REM sleep behaviour disorder (RBD) 6. However, even though this is a common problem, the diagnostic accuracy of sleep problems in PD patients is only 60% 7.

It has been recommended that assessment of PD should also include a disease-specific instrument for measurement of sleep disturbances 8. The Parkinson’s Disease Sleep Scale (PDSS) was developed on this background and also because the generic sleep assessment scales do not systematically address and quantify the most common sleep problems in PD patients 9. As such, this bedside tool can provide an indication for treatment of the sleep problems commonly accompanying PD.

Sleep and its associated factors in PD patients have been examined in several studies 6 10, but the predictive factors are found to vary and the results must be considered contradictory. One example is the relationship between sleep disturbance and fatigue: although it has been shown that sleep problems and fatigue frequently co-occur in PD, it has also been suggested that they should be regarded as distinct symptoms that must be understood and managed separately 11. Another and more consistent relationship is that between depression and sleep problems in PD 12 13 14. Symptoms of restless legs syndrome (RLS) are commonly reported by PD-patients, and such symptoms have also been associated with sleep problems 15. Finally, there are reports of an association between PD severity and sleep problems 9 however, these results are also inconsistent 5.

The purpose of this study was to examine self-reported sleep problems among PD patients in a community-based sample from Norway. Associated factors with sleep problems were also investigated, with special emphasis on disease stage, age and gender, mental health, fatigue and restless legs syndrome.

Methods

Material

All PD-patients living in the eastern part of Akershus county, Norway (320 000 inhabitants), were defined as the target population. Detailed information about the inclusion has been published previously (see 3). In short, a total of 413 PD patients were identified in the out-patient registry at the Department of Neurology, Akershus University Hospital; the only Neurological Department in the county. Only 243 patients fulfilled the inclusion criteria: PD diagnosis according to published diagnostic criteria 16, as well as mentally (Mini Mental State Examination, with a score ≥ 23 17) and physically able to complete interviews, self-report questionnaires and clinical examinations lasting for at least two hours. The data collection was organised as part of a yearly follow-up consultation. If patients did not want to participate, the regular consultations were conducted as scheduled. Due to financial restraints the inclusion period had to be shortened before the entire cohort was examined. The last forty-one eligible patients were therefore not invited to participate. Thus, 202 eligible patients were invited, 17 rejected, six did not answer, and three did not show up. In total, 176 eligible patients were included consecutively until the end of the inclusion-period, yielding a response rate of 87% (176/202). All patients were on dopaminergic medications. In addition, in total 8.5% were on treatment with anti-depressants/anticonvulsants with the intent of anti-depressive or pain-relieving effects 3.

Instruments

Through a structured interview, conducted as part of the clinical examination, information on PD, such as date of first symptom, date of diagnosis, and date of initiating therapy, were collected and recorded. After the clinical examination, patients were asked to complete a self-report questionnaire, which consisted of, among others, demographic information, and well-established instruments for assessment of sleep disturbances, fatigue, mental health problems and restless legs syndrome.

Staging of the disease was based upon the findings of the clinical examination and in accordance with present standards (Hoehn and Yahr Staging 18 and Unified Parkinson’s Disease Rating Scale, UPDRS 19). Cognitive functioning was assessed by the Mini Mental State Examination (MMSE) 17. All patients suffering from motor fluctuations (the fluctuating stage of the disease = on/off-periods) were examined during the on-period.

Sleep problems were assessed by the Parkinson’s disease Sleep Scale (PDSS) 9. The PDSS include 15 questions addressing the following 8 items: Overall quality of night’s sleep (question 1), sleep onset and maintenance insomnia (questions 2 and 3), nocturnal restlessness (questions 4 and 5), nocturnal psychosis (questions 6 and 7), nocturia (questions 8 and 9), nocturnal motor symptoms (questions 10–13), sleep refreshment (question 14) and daytime dozing (question 15). The response format is a 0–10 cm visual analogue scale, where 0 indicates that a symptom is severe and always experienced, while 10 means being free of symptoms. The score on each item is summarised into a total score giving a range of scores from 0 (most severe) to 150 (free of symptoms). Based on comparisons with polysomnography and other sleep questionnaires such as the Epworth Sleep scale, the PDSS appears to be a reliable tool to evaluate sleep characteristics in PD patients. 20 It is suggested that individuals obtaining an overall score below 82 or a score under 5 on any sub- item on the PDSS should be referred for formal sleep studies 21 22.

Fatigue was assessed by the Norwegian version of the Fatigue Questionnaire FQ 23 24. The FQ includes 11 items, and previous factor analyses support a two-factor solution; mental and physical fatigue. The sum score of responses to all 11 items is designated total fatigue, with minimum/maximum scores of 0/33. The FQ was originally validated in primary care, and has demonstrated good face- and discriminant validity as well as good and stable psychometric properties across populations 23. Reference data on fatigue levels from the Norwegian general population exists 24.

Mental health was assessed by the mental health (MH) subscale (5 items) of the Short Form 36 (SF-36) 25. The SF-36 has been validated in the general Norwegian population 26. Each item of the mental health subscale is scored on a 6 point category scale. The scores on all items are summed and transformed into a 0–100 scale (0 = poorest possible health state, 100 = best possible health state). A score below 50 is thought to indicate poor mental health.

Restless legs syndrome was assessed in a clinical interview by an experienced neurologist, based on the 4 essential criteria put forward by the International Restless Legs Syndrome Study Group 27, resulting in a dichotomous score (no/yes).

The study was approved by the Regional Committee for Medical Research Ethics. Appropriate informed consent was obtained from all respondents.

Statistical methods

Descriptive statistics for sleep problems, clinical and demographic variables were calculated. Further characteristics of PDSS were investigated, such as proportion of patients scoring under 82 points. The entire UPDRS was conducted, but only results from stage III will be reported. To analyse possible associations between sleep problems and characteristics of PD, demographic status, fatigue, mental health and co-morbidities, linear multiple regression was used. Crude bivariate analyses were conducted (data not shown). A stepwise approach was conducted; block one including demographic factors (age and gender), block two adding disease characteristics (disease duration and UPDRS part III) and block three adding other possible explanatory factors (fatigue, mental health, restless legs syndrome).

A significance level of 0.05 was chosen. Analyses were performed using STATA version 11.

Results

Sample characteristics

Of the 176 patients examined, 41% were women, and the mean age was 68.5 years (SD 8.8 years). The mean UPDRS part III was 22.3 (SD11.7). The mean Hoehn and Yahr stage was 2.11 (SD 0.86), the median is 2, and the interquartile range is 1. More specifically, 39.2% are in stage 1, 38.1% are in stage 2, 14.8% are in stage 3 and 8% in stage 4 of Hoehn and Yahr. For patients suffering from motor fluctuations (the fluctuating stage of the disease = on-/off-periods), all were examined during the on-period. The mean duration of PD was 7.5 years (SD 5.3) and the mean MMSE was 28 (range 23–30). The mean mental health SF-36 score was 72.3 (SD 18.8), and the mean total fatigue score was 15 (SD 5.0). RLS was reported by 27% of the patients, and was significantly more common in patients with Hoehn and Yahr stage 1–2 (26%), compared to those with stage 3–4 (10%).

Sleep problems in PD patients

The overall mean total PDSS score was 102.8 (SD 23.3), and 17% (N = 32) of the patients had a total PDSS score under 82. A more detailed examination of the PDSS sub-scales and proportion of patients scoring below 5 are shown in Table 1). In total, 70% had a total score under 5 on one or more items of the PDSS. There were no significant differences in Hoehn and Yahr stage 1–2 vs 3–4 for any of the PDSS items.

Table 1

mean (± SD)

% scoring <5

Item 1: Quality of nights sleep

6.0 (2.9)

Item 2: Sleep onset and maintenance insomnia

7.0 (2.5)

Item 3: Nocturnal restlessness

5.7 (2.8)

Item 4: Nocturnal psychosis

8.2 (2.0)

Item 5: Nocturia

5.8 (2.0)

Item 6: Nocturnal motor symptoms

7.5 (2.0)

Item 7: Sleep refreshment

6.1 (3.1)

Item 8: Daytime dozing

7.1 (3.3)

Total

102.8 (23.3)

Factors associated with sleep problems are shown in Table 2. Only total fatigue score, RLS and mental health problems were factors associated with PDSS score.

Table 2

Block one

Block two

Block three

Variable

Beta

p-value

Beta

p-value

Beta

p-value

Age (yrs)

0.12

0.1

0.14

0.07

0.01

0.1

Gender

−0.04

0.6

-.05

0.5

0.07

0.2

Disease duration (yrs)

−0.12

0.13

−0.09

0.2

UPDRS sum part III

−0.15

0.07

−0.05

0.5

Mental health (SF-36)

0.36

<0.001

Fatigue (FQ)

−0.17

0.02

Restless legs syndrome

−0.34

<0.001

The adjusted R2 for the final model was 0.39.

Discussion

Sleep problems were common among the PD patients examined. No association was found between PD severity and sleep problems in this community-based population of medicated patients, of whom 71% had a mild disease. In contrast in this group, the sleep problems were related to mental health problems, fatigue and RLS.

The prevalence of sleep problems among PD patients depends on the population examined and the definition of sleep problems (i.e. the assessment method). In Norway, the prevalence of PD is about 111 per 100.000 inhabitants 28, suggesting about 355 patients in our recruitment area. Thus, our initial population of 345 was probably close to all cases in the catchment area. The response rate was 87%. We therefore consider the present study to have good external validity for a community-based study, although it was conducted at a single institution. On the other hand, although this study might be representative for the Norwegian population, the results are not generalizable to the global PD population at large. For sleep assessment use, the PDSS was used. The clinimetric properties of the instrument are valid and widely used. However, there are some limitations of the instrument, as it does not measure some of the sleep disorders, such as REM behaviours disorder, and others may be underdiagnosed, such as diurnal somnolence.

A limitation of the generalizability is that the study does not address sleep problems in PD patients with dementia or in patients otherwise unable to utilize self-report instruments for data collection. Another limitation of the study is that there is no control population, and since PDSS is a disease-specific scale, there are no Norwegian norm data available. Furthermore, all patients are examined when in medicated state, and we did not further specifically explore the relationship between the PD medications and sleep. The treatment of the disease may affect the sleep disorder; low doses of dopamine agonists has been shown to promote sleep, whereas high doses both during the day and in the evening may lead to increased nocturnal awakenings, reduced slow-wave sleep, and decreased sleep continuity 29.

In the current study, only 17% of the patients had a PDSS score under 82, which is the recommended clinical cut-off for the PDSS. However, when examining the specific PDSS sub-scales, over a third of the sample reported poor quality of sleep, nocturnal restlessness, and poor sleep refreshment. In total, 70% had a total score under 5 on one or more items of the PDSS. Consequently, several of these patients are candidates for referral to further formal sleep tests according to the recommendations for the use of PDSS. The availability of objective sleep studies for verification and established treatment options for sleep problems should prompt physicians to refer PD patients with specific sleep complaints to PSG and sleep apnoea studies. Still, in Norway there is a strikingly low rate of PD-patients referred to the department of neurophysiology at Akershus university hospital, even though the high prevalence of sleep problems in this patient group is widely accepted.

In the group-wise regression model, only three factors were significantly associated with PDSS score, namely poor mental health, restless legs syndrome, and fatigue. Our finding that mental health problems strongly predicted sleep problems in PD patients was not surprising. The close relationship between the two is well known, both in the general population 30 and in patients with PD 31 32. Although the direction of causality between them is often difficult to establish, a large population-based longitudinal study recently showed that both insomnia and depression strongly and similarly predicted the onset of the other 33. In PD, however, the extent of these associations and how they relate to the clinical heterogeneity in PD is not fully understood, and there is therefore a need for longitudinal studies to examine the nature of the entwined relationship between sleep problems and depression in this patient group.

In the current study, sleep problems as measured by the PDSS, was significantly associated with fatigue, which is in accordance with other studies 34. In contrast, studies assessing daytime somnolence (such as the Epworth Sleepiness Scale) rather than nocturnal problems, generally do not find such an association 35 36. As fatigue is an undifferentiated problem present in the general population and associated with several somatic complaints, the entwined relationship between sleep problems and fatigue needs to be elucidated.

In this study, the prevalence of RLS was 27% and an association was found with sleep problems. Few have examined this association in PD patients, and previous results are contradictory. However, those using a disease specific sleep scale, such as SCOPA-Sleep or PDSS report an association 37 38, while those finding no association tended to use generic sleep assessment scales, such as the Epworth Sleepiness Scale or the Pittsburgh Sleep Quality Index 15 39. The PDSS has one item on nocturnal restlessness (item 4), and as in other studies those with RLS have significantly lower score on this item 22. The relationship between PDSS and RLS is still significant when item4 is removed from the analysis (data not shown). In line with earlier suggestions, the PDSS can be helpful in identifying RLS symptoms in PD patients.

An interesting and surprising finding was that stage of disease, measured by both Hoehn and Yahr and UPDRS sum part III separately, was not associated with PDSS score in this population. This finding is in disagreement with other studies examining the association between sleep problems and PD severity 9 22. However, in this community-based study of medicated patients, 71% had a mild disease. We would have expected that patients with severe PD-symptoms also reported more sleep problems than patients with less severe PD. It should be noted that the current study did not include the most severe PD patients (Hoehn and Yahr stage 5), and as such, it might be that sleep problems are more prevalent among the most severely affected PD patients.

Conclusion

The current findings call for increased awareness of sleep problems in PD patients, especially focusing on the association with mental health problems, fatigue and RLS.

Competing interest

None of the authors have competing interests.

Authors’ contribution

AGB and JHL participated in the conception, organization and execution of the data collection. ES and BS had the idea for the study, and performed the statistical analyses and wrote the first draft, while AGB, JHL and KKB participated in review and critique of the manuscript. All authors read and approved the final manuscript.

Financial support

The work was supported by a grant from Ullevål University Hospital Oslo, Norway which made the carrying out of the study possible.

Acknowledgements

The authors give special thanks to Professor Kjell Magne Tvedt at the Cancer Centre, Oslo University Hospital, Vibeke Schou Jensen at Oslo University Hospital Ullevål, Norway, and Anne Rønningen at Akershus University Hospital for their support of the study. The authors also wish to acknowledge the patients who participated in the study.

Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Groupde RijkMCLaunerLJBergerKBretelerMMDartiguesJFBaldereschiMFratiglioniLLoboAMartinez-LageJTrenkwalderCNeurology200054S21S2310854357Non-motor symptoms of Parkinson’s disease: diagnosis and managementChaudhuriKRHealyDGSchapiraAHLancet Neurol2006523524510.1016/S1474-4422(06)70373-816488379Pain in Parkinson’s disease: Prevalence and characteristicsBeiskeAGLogeJHRonningenASvenssonEPain200914117317710.1016/j.pain.2008.12.00419100686Fatigue in Parkinson’s disease: prevalence and associated factorsBeiskeAGLogeJHHjermstadMJSvenssonEMov Disord2010252456246010.1002/mds.2337220976741A community-based study of sleep disorders in patients with Parkinson’s diseaseTandbergELarsenJPKarlsenKMov Disord19981389589910.1002/mds.8701306069827612Sleep disturbances in Parkinson disease and their potential role in heterogeneityGunnDGNaismithSLLewisSJJ Geriatr Psychiatry Neurol20102313113710.1177/089198870935859120101072Non-recognition of depression and other non-motor symptoms in Parkinson’s diseaseShulmanLMTabackRLRabinsteinAAWeinerWJParkinsonism Relat Disord2002819319710.1016/S1353-8020(01)00015-312039431Clinical assessment of nocturnal disability in Parkinson’s disease: the Parkinson’s Disease Sleep ScaleChaudhuriKRMartinez-MartinPNeurology200463S17S2010.1212/WNL.63.8_suppl_3.S1715505136The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s diseaseChaudhuriKRPalSDiMarcoAWhately-SmithCBridgmanKMathewRPezzelaFRForbesAHoglBTrenkwalderCJ Neurol Neurosurg Psychiatry20027362963510.1136/jnnp.73.6.629175733312438461Mood and sleep in Parkinson’s diseaseBorekLLKohnRFriedmanJHJ Clin Psychiatry20066795896310.4088/JCP.v67n061316848656Sleep and fatigue in Parkinson’s diseaseFriedmanJHChouKLParkinsonism Relat Disord200410Suppl 1S27S3515109584Sleep disturbances in Parkinson’s diseaseMenzaMDobkinRDMarinHBienfaitKMov Disord201025Suppl 1S117S122284005720187236Sleep disorders, pain, and depression in Parkinson’s diseaseStarksteinSEPreziosiTJRobinsonRGEur Neurol19913135235510.1159/0001166921756757Sleep disorders and depression in patients with Parkinson’s diseaseHappeSSchrodlBFaltlMMullerCAuffEZeitlhoferJActa Neurol Scand200110427528010.1034/j.1600-0404.2001.00024.x11696021Exploring the relationship between Parkinson disease and restless legs syndromeOndoWGVuongKDJankovicJArch Neurol20025942142410.1001/archneur.59.3.42111890847Clinical diagnosis of Parkinson’s disease. Proposal of diagnostic subgroups classified at different levels of confidenceLarsenJPDupontETandbergEActa Neurol Scand1994892422510.1111/j.1600-0447.1994.tb01508.x8042440“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinicianFolsteinMFFolsteinSEMcHughPRJ Psychiatr Res19751218919810.1016/0022-3956(75)90026-61202204Parkinsonism: onset, progression and mortalityHoehnMMYahrMDNeurology19671742744210.1212/WNL.17.5.4276067254Recent developments in Parkinson’s diseaseFahnSEltonRLMembers of the UPDRS Development Committee: unified Parkinson’s disease rating scaleFlorham Park: MacMillan Health Care InformationFahn S, Marsden CD, Calne DB, Lieberman A1987153163Validation of the Parkinson’s disease sleep scale in Japanese patients: a comparison study using the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale and PolysomnographyUemuraYNomuraTInoueYYamawakiMYasuiKNakashimaKJ Neurol Sci2009287364010.1016/j.jns.2009.09.01519804890SCOPA-sleep and PDSS: two scales for assessment of sleep disorder in Parkinson’s diseaseMartinez-MartinPVisserMRodriguez-BlazquezCMarinusJChaudhuriKRvan HiltenJJMov Disord2008231681168810.1002/mds.2211018709672Clinical usefulness of the Parkinson’s disease sleep scaleTseWLiuYBarthlenGMHalbigTDTolgyesiSVGraciesJMOlanowCWKollerWCParkinsonism Relat Disord20051131732110.1016/j.parkreldis.2005.02.00615882956Development of a fatigue scaleChalderTBerelowitzGPawlikowskaTWattsLWesselySWrightDWallaceEPJ Psychosom Res19933714715310.1016/0022-3999(93)90081-P8463991Fatigue in the general Norwegian population: normative data and associationsLogeJHEkebergOKaasaSJ Psychosom Res199845536510.1016/S0022-3999(97)00291-29720855Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructsMcHorneyCAWareJEJrMed Care19933124726310.1097/00005650-199303000-000068450681Short form 36 (SF-36) health survey: normative data from the general Norwegian populationLogeJHKaasaSScand J Soc Med1998262502589868748Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of HealthAllenRPPicchiettiDHeningWATrenkwalderCWaltersASMontplaisiJSleep Med2003410111910.1016/S1389-9457(03)00010-814592341The epidemiology of Parkinson’s disease in the county of Rogaland, NorwayTandbergELarsenJPNesslerEGRiiseTAarliJAMov Disord19951054154910.1002/mds.8701005038552103Dopamine agonists and sleep in Parkinson’s diseaseCantorCRSternMBNeurology200258S71S7810.1212/WNL.58.suppl_1.S7111909988Sleep and emotions: a focus on insomniaBaglioniCSpiegelhalderKLombardoCRiemannDSleep Med Rev20101422723810.1016/j.smrv.2009.10.00720137989Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson’s diseaseSuzukiKMiyamotoMMiyamotoTOkumaYHattoriNKameiSYoshiiFUtsumiHIwasakiYIijimaMParkinsonism Relat Disord200915151910.1016/j.parkreldis.2008.02.00218359262Insomnia in Parkinson’s disease: frequency and progression over timeGjerstadMDWentzel-LarsenTAarslandDLarsenJPJ Neurol Neurosurg Psychiatry200778476479211785117098844SivertsenBSaloPMykletunAHysingMPallesenSKrokstad SThere and back again: Exploring the causal link of depression and insomnia2011Fatigue in Japanese patients with Parkinson’s disease: a study using Parkinson fatigue scaleOkumaYKameiSMoritaAYoshiiFYamamotoTHashimotoSUtsumiHHatanoTHattoriNMatsumuraMMov Disord2009241977198310.1002/mds.2273119672993Towards an understanding of fatigue in Parkinson diseaseHagellPBrundinLJ Neurol Neurosurg Psychiatry20098048949210.1136/jnnp.2008.15977219204024Fatigue in Parkinson’s disease is not related to excessive sleepiness or quality of sleepHavlikovaEvan DijkJPRosenbergerJNagyovaIMiddelBDubayovaTGdovinovaZGroothoffJWJ Neurol Sci200827010711310.1016/j.jns.2008.02.01318371981Prevalence and clinical profile of restless legs syndrome in Parkinson’s diseaseVerbaanDvan RoodenSMvan HiltenJJRijsmanRMMov Disord2010252142214710.1002/mds.2324120737549Restless legs syndrome in Parkinson’s diseaseGomez-EstebanJCZarranzJJTijeroBVelascoFBarcenaJRoucoILezcanoELachenMCJaureguiAUgarteAMov Disord2007221912191610.1002/mds.2162417579369Case–control study of restless legs syndrome and quality of sleep in Parkinson’s diseaseLooHVTanEKJ Neurol Sci200826614514910.1016/j.jns.2007.09.03317942122

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/12/71/prepub